ACW FY2026 results and outlook
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The report indicates a net loss for the year, primarily due to significant research and development costs associated with advancing Xanamem. The outlook for the upcoming year focuses on completing the XanaMIA trial and pursuing strategic partnerships to enhance the value of Xanamem.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- ACW Appendix 4E and 2026 annual report
- Appendix 4G
- Corporate Governance Statement
- Appendix 3Y - Dr George Morstyn
- Application for quotation of securities - ACW
Later from Actinogen Medical
- Appendix 3Y-Dr Geoffrey Brooke
- Proposed issue of securities - ACW
- ACW unlisted options fully underwritten
- Response to ASX Price Query
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical